FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation
Key facts
- Who runs it
- Vesalius Cardiovascular Inc.
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 5 people, planned
- Started
- Aug 2026
- Expected to end
- Apr 2032
- Type of study
- Interventional
- Treatments tested
- Transcatheter Mitral Valve Repair
- Record updated
- 19 August 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age ≥ 19 years
- Moderate to severe (≥3+) or severe (≥4+) degenerative mitral valve regurgitation (per American Society of Echocardiography (ASE) guidelines, depicted in Figure 14)
- New York Heart Association (NYHA) Functional Class II, III, or Ambulatory (IV)
- Elevated risk for surgical mitral valve repair: Society of Thoracic Surgery (STS) predicted risk of mortality (PROM) of ≥6% as determined by the STS Risk Calculator for Surgical Repair of Primary Mitral Regurgitation [1], as well as patient operative risk assessment by the Heart Team
- Suitable anatomy for the Vesalius TMVr System as determined by pre-procedure imaging
- Willing to adhere to study follow-up schedule for up to 5 years
- Written informed consent provided
Who cannot take part
- Anatomy ideally suitable for other approved transcatheter therapy (i.e. TEER candidate)
- Previous valvular surgery
- Previous atrial septal surgery
- Previous endovascular structural procedure(s) and/or device(s) within 6 months
- Contraindication to anticoagulation / antiplatelet therapy
- Concomitant severe tricuspid regurgitation
- Dialysis-dependent renal insufficiency
- Leaflet perforation
- Life expectancy <1 year due to non-cardiac comorbidities
- Presence of other anatomic, comorbid conditions, or other medical conditions that could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results, in the opinion of the Heart Team
- LV ejection fraction < 30%
- Active bacterial endocarditis within 60 days of planned index procedure
- Body Mass Index (BMI) ≥ 45 kg/m2
- Severe mitral annular calcification (MAC) prohibiting device implantation
- Severe annulus or leaflet calcification
- Patients with sensitivity to nickel or contrast media
- Absence of conventional medial and lateral papillary muscle groups
- Femoral vein cannot accommodate a 29 F catheter
- Contraindication to Transoesophageal echocardiography (TEE)
- Participation in other clinical investigation
- Pregnant or planning to become pregnant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This first-in-human study evaluates the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with degenerative mitral regurgitation. The study will enroll patients who are at high or prohibitive risk for conventional surgical repair or replacement of the mitral valve. Participants will receive implantation of the Vesalius TMVr System and will be followed to assess clinical outcomes, device performance, and any adverse events.
The group in the trial
- Vesalius TMVr SystemTreatment being tested
Participants in this arm will undergo implantation with the Vesalius Transcatheter Mitral Valve Repair (TMVr) System according to the study protocol. All procedures will be performed by trained interventional cardiologists, and participants will be followed for safety, device performance, and clinical outcomes at predefined intervals.
Treatment: Transcatheter Mitral Valve Repair
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A First-in-Human Investigational Testing Authorization Study Evaluating the Safety and Performance of the Vesalius Transcatheter Mitral Valve Repair System in Patients With Severe, Symptomatic Degenerative Mitral Regurgitation
- Record updated
- 19 August 2026